Prostate Cancer Research
News: Research and Therapeutics
- 3/10/2015Statins May Help Improve Prostate Cancer Survival: Study | Finds the cholesterol-lowering drugs linked to slower progression of disease
- 2/24/2015Did PSA Test's Decline Spur Rise in Prostate Cancers? | Researchers report 3 percent annual rise in intermediate- and high-risk cases.
- 2/23/2015Watch-and-Wait Strategy May Be Riskier for Certain Prostate Cancers | Study found lower survival for intermediate-risk disease, compared to low-risk cases.
- 2/23/2015Testicular Cancer May Raise Prostate Cancer Risk: Study | But it's too soon to make any recommendations, and overall risk is low, researcher says.
- 2/19/2015More Americans Surviving Cancer Today Than 20 Years Ago | Study shows biggest improvements in people diagnosed between ages 50 and 64.
- 2/19/2015Are Too Many Prostate Cancer Patients Receiving Treatment? | Study also raises concerns about possible overuse of radiation therapy.
- 1/27/2015MRI Improves Prostate Cancer Biopsy Accuracy, Study Finds | New technology spots more aggressive cancer, but fewer low-risk cases
- 1/07/2015Strategy Might Thwart Resistance to a Common Prostate Cancer Treatment | Small study suggests that alternating testosterone levels may make hormonal therapy work longer
- 9/17/2014DNA Blood Test Might Identify Status of Prostate Cancer | May help doctors pinpoint best treatment, researchers say
- 9/15/2014New Gene Variants for Prostate Cancer Identified | 23 new variants associated with increased risk of the disease, study shows
- 9/15/2014Male Pattern Baldness Tied to Prostate Cancer, Study Suggests | Testosterone might be the link between the two, but more research needed to prove a connection
- 7/14/2014Depression May Make It Harder to Beat Prostate Cancer | Men with both conditions have worse survival odds, study contends
- 7/2/2014Making Science Real: Scientists Moving Forward in Addressing Research Integrity; Learning from Past Mistakes | Poor scientific reproducibility is a product of poor reagents, sloppiness, selective publishing of data, and on occasion – outright fraud.
- 6/5/2014The Prostate Cancer Foundation Congratulates PCF Investigator Dr. Nima Sharifi on his 2014 award from the AACR for Outstanding Achievement in Cancer Research | At the 2014 AACR Annual Meeting, Prostate Cancer Foundation Investigator Dr. Nima Sharifi was honored with the 34th Annual AACR Award for Outstanding Achievement in Cancer Research
- 6/5/2014The Prostate Cancer Foundation Congratulates PCF Investigator Dr. Levi Garraway on both his AACR award—the Jane Cooke Wright Lectureship, and his Paul Marks Prize for Cancer Research from Memorial Sloan-Kettering Cancer Center | Prostate Cancer Foundation-funded Investigator Dr. Levi A. Garraway takes home two awards: The Jane Cooke Wright Lectureship Award at the 2014 AACR Annual Meeting & Memorial Sloan-Kettering Cancer Center’s Paul Marks Prize for Cancer Research
- 6/5/2014How the immune system can be harnessed to kill cancer | Understanding and improving on immunotherapies was a major focus at the 2014 AACR Annual Meeting.
- 5/29/2014Advances in Prostate Cancer Research from the 2014 AACR Annual Meeting | At the 2014 AACR Annual Meeting held in San Diego, CA this spring, Prostate Cancer Foundation-funded investigators discussed recent progress and exciting new studies regarding prostate cancer biology and treatment.
- 5/14/2014Finding Cancer Solutions, One Cell at a Time | Hot new technologies and methods are making leaps forward in studying individual cancer cells—which will help prevent drug resistance to therapy and identify new drug targets
- 3/28/2014PCF researchers discover molecular crosstalk that prostate cancer cells use to survive radiation therapy; plan steps to halt that “conversation” | Prostate Cancer Foundation-funded researchers published two studies this fall that help explain why androgen deprivation therapy improves survival when given with radiation therapy
- 3/27/2014 Slight Drop in Rate of Advanced Cancers, CDC Says | Number of cases where tumors have spread beyond origins declined, but experts say more can be done
- 2/18/2014 "Delivering a Triple-Knockout Punch to Prostate Cancer—A novel cancer immunotherapy approach receives a $1 million Movember-Prostate Cancer Foundation Challenge Award" | Coaxing our natural immune system to fight off cancer cells in the body has been historically and frustratingly difficult
- 1/28/2014 Drug May Extend Survival for Men With Advanced Prostate Cancer | Study participants hadn't received any treatment with chemotherapy
- 1/16/2014 Patient-Centered Drug Development (video) | Doc, How will this this anti-cancer drug make me feel?
- 1/10/2014 Two-thirds of new FDA-approved drugs to treat prostate cancer driven by Prostate Cancer Foundation support | The Journal of Clinical Oncology has just published an item detailing the Prostate Cancer Foundation's deep involvement in bringing new drugs against prostate cancer to market
- 1/10/2014 An Aspirin a Day to Keep the Prostate Cancer at Bay? | PCF Young Investigator, Dr. Jennifer R. Rider of Brigham and Women's Hospital and the Harvard School of Public Health looks into what impact aspirin therapy might have on prostate cancer
- 1/9/2014 Geraldine Gueron, a Prostate Cancer Foundation Young Investigator, has been named by MIT Technology Review as a Top Innovator Under 35 for 2013 | The Massachusetts Institute of Technology's Technology Review 35, or MIT TR35, award is an "annual celebration of people who are driving the next generation of technological breakthroughs."
- 10/30/2013 Promising Nanomedicine Advances to Phase II Clinical Trials | Docetaxel has long been used to treat advanced forms of prostate cancer; now an ingenious targeted drug platform will deliver this chemotherapeutic directly to tumors, allowing higher dosing with fewer side effects
- 10/24/2013 Cool Technology: Stretchy Electronics and Sensors that Can Dissolve in Your Body | A 21st century interface of engineering and oncology may bring better medicine to patients. Learn about electoceuticals and how they may help prevent infections, and why next-generation electronics that can stretch to fit over catheters or dissolve once no longer needed may benefit patients
- 7/24/2013 Subtype of Highly Aggressive Prostate Cancer Increasing; Tied to Drug Resistance to Hormone Therapy | Novel drug being tested in multi-site Phase II clinical trial to treat men with this aggressive form of prostate cancer known as neuroendocrine prostate cancer
- 7/24/2013 Xofigo Results Published in New England Journal of Medicine – Explanatory Video Accompanies Publication | Explanatory Video Accompanies Publication | The Prostate Cancer Foundation has repeatedly reported on this drug’s development and movement to market
- 7/2/2013 Breakthrough in Nano-Medicine Chemotherapy Drug Delivery in Phase II Trials | Think of this nanoparticle technology as a Chemotherapy ExpressLine Bus Service
- 6/24/2013 With FDA-approval of Xofigo, many men with advanced prostate cancer can expect improved quality of life (Video) | Listen as Doctors Discuss Xofigo in greater detail
- 6/10/2013 Prolaris Prostate Cancer Test Highly Predictive of Tumor Lethality | Summary Results of five studies of test presented at this year’s ASCO meeting in Chicago
- 6/4/2013 Personalizing Cancer Care: PARP Inhibitor + Hormone Therapy for Advanced Prostate Cancer | Study to determine if prostate cancer patients with prevalent gene-fusion mutation benefit from addition of PARP inhibitors to Hormone Therapy
- 5/23/2013 New Genetic Test to Diagnose Highly Lethal Form of Prostate Cancer Enters Commercial Development; May Lead to Increased Survival | The occurrence of a rare and highly aggressive form of prostate cancer known as neuroendocrine prostate cancer (NEPC) is increasing
- 5/20/2013 A Layman's Guide to Prostate Cancer Genes | Prostate Cancer Genes Begin to Tell Their Story
- 5/15/2013 Another new drug that extends survival time for men with advanced prostate cancer gains FDA approval | Xofigo (radium-223) is the second prostate cancer drug to treat metastatic disease that has come to market during the past year; the first bone-targeted drug to improve survival
- 5/13/2013 Taking the Lethal out of Prostate Cancer; plus Entirely New Class of Drug Shows Promise Against Advanced Disease (video) | Entirely New Class of Drug Shows Promise Against Advanced Prostate Cancer
- 5/8/2013 New Test Can Better Tell Need For Surgery vs. Active Surveillance | Prostate Cancer Foundation funded early research that underpinned test’s development.
- 5/8/2013 New 17-gene test enhances ability to predict aggressiveness of prostate cancer; may spare men unnecessary surgery/radiation | Prostate Cancer Foundation funded early research that underpinned test’s development
- 5/2/2013 Statins May Reduce Prostate Cancer Deaths | The role of statins in mitigating prostate cancer risks has been debated often during the past few years
- 4/26/2013 Can Botox Tame Prostate Cancer? | Botox shriveled tumor cells in men prior to surgery; injections of the drug into tumor may enhance effects of radiation therapy
- 4/25/2013 Zytiga is Most Used First-Line Treatment for Stage IV Prostate Cancer | Market data released this week shows the new drug’s share of the first-line prostate cancer market has steadily increased to 30 percent since its launch in 2011
- 4/22/2013 News Roundup—prostate cancer news makes headlines at the annual meeting of the American Association for Cancer Research | Selenium-Prostate Cancer Link Again Under Debate
- 4/22/2013 Cancer Centers Race to Map Patient’s Genes | Researchers now acknowledge that studying the few ‘exceptional responders’ in failed clinical trials can yield new insights into cancer
- 4/19/2013 Cancer Researchers Revisit 'Failed' Clinical Trials and Begin Study of the One to Ten Percent of Patients Who Responded to Treatment | The ability to map the genes of cancer patients and determine the specific genotype (variety) of their tumors is rapidly moving
- 4/15/2013 Prostate Cancer Foundation Young Investigators Advance Cancer Research at the 2013 AACR in Washington | This year, AACR presentations related to prostate cancer were chock full of Prostate Cancer Foundation Young Investigators
- 4/8/2013 Rally for Medical Research | The Prostate Cancer Foundation (PCF) is one of over 200 partnering organizations supporting this important event.
- 4/5/2013 Third-Generation Device Significantly Improves Capture of Circulating Tumor Cells | A new system for isolating rare circulating tumor cells (CTCs) -- living solid tumor cells found at low levels in the bloodstream -- shows significant improvement over previously developed devices and does not require prior identification of tumor-specific target molecules
- 4/5/2013 Study Changes the Way Doctors Practice | A new study shows that continuous hormone therapy (androgen deprivation therapy) helps men more than intermittent or pulsed hormone therapy.
- 4/5/2013 The Link Between Early Baldness and Prostate Cancer | Researchers have long known about the potential link between baldness and the risk of prostate cancer, but studies have been conflicting
- 4/3/2013 A Year After Common, Novel SPOP Prostate Cancer Gene Mutation Identified, Researchers Determine Its Route to Cancer | When SPOP is mutated it no longer can act as a tumor suppressor gene
- 3/13/2013 Delivering on the Promise to Young Scientists | The young do not know enough to be prudent
- 3/8/2013 Markers May Indicate Occult High-Grade Prostate Cancer | Epigenetic changes in benign tissue sampled during prostate biopsy confirmed as "field effect" biomarkers of undetected tumor
- 2/11/2013 More Data Links Prostate Cancer With Dairy Consumption | Prior studies have shown that higher overall milk intake is associated with a greater risk of developing prostate cancer
- 2/01/2013 PCF-Funded Investigator to Lead New Institute for Precision Medicine | Precision medicine is the ultimate goal in treating prostate cancer so we can cure more and overtreat less
- 1/25/2013 New Y Chromosome Research Yields Insight Into Prostate Cancer Development | A large international 10-year project launched last year, titled the Human Proteome Project, ambitiously aims to map all proteins produced by genes on human chromosomes
- 1/24/2013Cost-Effectiveness Study Compares Surgery and Radiation Therapy for Localized Prostate Cancer—Small Differences in Outcomes, Big Differences in Cost | Dr. Cooperberg explains that they ran and reran the men through their various treatment algorithms and that a certain number of men would wind up in each possible health state
- 1/22/2013 Investigational Agent Orteronel (TAK700) Holds Promise in the Post-Abiraterone, Post-Enzalutamide Era | The past year has been exciting for prostate cancer patients with newer, more potent agents such as abiraterone and enzalutamide being added to the prostate cancer treatment armamentarium
- 1/17/2013 Focal Therapy for Prostate Cancer Explained in Research Review | Researchers from Duke University Medical Center studied the evolution of focal therapy as a reasonable option for men with clinically localized, low-grade disease
- 1/15/2013 Kaiser Permanente Study Finds Changes in Prostate Specific Antigen Levels over Time can Help Predict Aggressive Prostate Cancer | Measurements taken over time of prostate specific antigen, the most commonly used screening test for prostate cancer in men
- 1/14/2013 Mapping PCa’s Genetic Landscape Just Got a Bit Easier and Potentially Less Expensive | Cancer genetics researchers study tumors for clues; they want to know how the tumor got there in the first place
- 1/8/2013 New Center for Prostate Cancer to be led by PCF Researcher Dr. Ashutosh Tewari | Researcher, mentor and long-time friend to PCF, Dr. Ashutosh Tewari will lead the new Center for Prostate Cancer at New York-Presbyterian/Weill Cornell Medical Center
- 12/21/2012 Prostate Cancer: What Did We Learn From the 2012 Annual Scientific Meeting of ASCO? | In recent years, management of prostate cancer has benefited from an expanding array of new pharmacological options
- 12/20/2012 Epigenetics and Cancer | An Enzyme’s Functional Switch May Fuel Treatment-Resistant Prostate Cancer; Drug Target More Clearly Limned
- 12/19/2012 New England Journal of Medicine Publishes Positive Phase III Clinical Results for Zytiga (abiraterone) in Men Without Prior Chemotherapy—Should Bolster Medical Reimbursements | The study was a multinational, double-blind, randomized evaluation of 1,088 men assigned to receive either Zytiga and prednisone, or placebo plus prednisone.
- 12/18/2012 California a Leading State for Research Into Cancer Afflicting Gov. Brown | The study was a multinational, double-blind, randomized evaluation of 1,088 men assigned to receive either Zytiga and prednisone, or placebo plus prednisone
- 12/17/2012 First Patient Inducted into Phase II Clinical Trial Evaluating Galeterone | Building on the success of Phase I clinical trials, Tokai Pharmaceuticals has advanced its lead prostate cancer drug for the treatment of advanced disease into Phase II trials this week.
- 12/11/2012 Childhood Leukemia Researcher Makes Headlines, Now Works toward Prostate Cancer | One of the biggest challenges of prostate cancer is the diagnostic process, with respect to both finding tumors within the prostate and obtaining the most precious biopsy samples
- 12/11/2012 Promising Phase III Clinical Trial Successfully Enrolls 1,200 Patients | Tasquinimod, or TASQ, is an oral experimental treatment for men with metastatic treatment resistant prostate cancer
- 12/07/2012 Common Bacteria Examined in Prostatectomy Samples | In this preclinical study, the researchers found that their novel drug was indeed activated by PSA in prostate cancer cells and lead to P13K inhibition and cancer cell death
- 12/04/2012 Promising Results for 1st Prostate Cancer-Targeted Prodrug Against Signaling Pathway (PI3K) Associated with Substantial Number of Prostate Tumors | In this preclinical study, the researchers found that their novel drug was indeed activated by PSA in prostate cancer cells and lead to P13K inhibition and cancer cell death
- 12/03/2012 PET Scans to Image Prostate Cancer Advance Toward Mainstream Clinical Use | This project was partially supported by a PCF Creativity Award made possible through generous support of Movember
- 11/29/2012 The Microfluidic VerIFAST | On October 26, 2012, PCF-funded Young Investigator Joshua Lang, MD presented data on the VerIFAST platform and the development of circulating tumor cell isolation and staining technology.
- 11/29/2012 Vitamin D Mechanism of Action Discovered by McGill University | Vitamin D has long been believed to play an important role in prostate and other cancers, though its mechanism of action had yet to be verified.
- 11/26/2012 Epigenetics and Prostate Cancer – New Findings May be of Particular Importance for Men Lacking a Common Genetic Fusion Abnormality | Determining what drives prostate cancer development and progression is the key to finding ways to alter than course and prevent deaths from this disease.
- 11/16/2012 Glutamate, an Agent in Cancer Metabolism, Identified as a Biomarker for Prostate Cancer | There is a critical unmet medical need to identify disease biomarkers that can efficiently report on the underlying biology of an individual patient’s cancer.
- 11/16/2012 Prostate Cancer Antibody Attacks Metastatic, Treatment-Resistant Disease | Daniel Petrylak, MD, of Yale University Medical Center and a past PCF-funded investigator, led a research study evaluating an antibody-drug that targets prostate-specific membrane antigen (PSMA)
- 11/16/2012 Recurrent Prostate Cancer May Be Explained Through Deeper Understanding of Androgen Receptor | Androgens are male hormones that fuel the growth and spread of prostate cancer
- 11/16/2012 Bar Code Tests Spot Aggressive Prostate Cancers | Aside from curing prostate cancer, the holy grail of this disease is to determine which cancers require aggressive treatments
- 11/1/2012 Memorial Sloan-Kettering Researchers Discover Prostate Cancer Disease Pathways Regulate Each Other | Researchers discover a specific combination of inhibitors which cause tumor recession in mouse models.
- 10/26/2012 Stat5 Predicts Early Disease Recurrence and Prostate Cancer Specific Deaths in Patients After Radical Prostatectomy | There is an urgent unmet medical need to identify robust markers to identify patients whose prostate cancer will recur after initial treatment and progress to aggressive disease.
- 10/26/2012 Mystery of Trop2 Protein Unveiled | The proteinTrop2 has long been considered a vital component to understand disease progression in several cancers.
- 10/5/2012 New Data Shows Added Benefits for Prostate Cancer Drug Enzalutamide | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/5/2012 Novel Anti-androgen Drug Shows Potential Anticancer Effects in 87% of Men with Advanced Form of Prostate Cancer in Early Clinical Testing | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/4/2012 Common Drug Used to Treat Diabetes May Benefit Subset of Prostate Cancer Patients | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/4/2012 Novel Anti-Sense Drug Lowers PSA Levels and Delays Disease Progression in a Phase II Clinical Trial | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/2/2012 Protein Found in Prostate Cancer May Promote Cancer Growth and Progression | The protein PARP1 is known to play a crucial role in DNA repair.
- 10/2/2012 Novel Radiopharmaceutical Shows Survival and Quality of Life Benefit to Men with Metastatic PCa | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/1/2012 The War on Cancer Reboots | It's been a fight that has been going on for four decades, but new technologies are allowing us to get a better understanding of how cancers work, reports Alex Philippidis in Streetwise's Life Sciences Report.
- 9/26/2012 MD Anderson Cancer Center Initiates “Moon Shot” Program to Increase Patient Survival over Coming Decade | According to MD Anderson president Ronald DePinho, the institution has "tens of millions of dollars" to get started and plans to spend up to $3 billion over the next 10 years.
- 8/10/2012 PCF-Funded Young Investigator Awarded by University for Exemplary Research Progress Made in Prostate | 2010 LeFrak Family PCF Young Investigator Dr. Himisha Beltran, assistant professor of medicine at Weill Cornell Medical College, was honored by the institution with The 21st Annual Department of Medicine Investigator Award.
- 8/8/2012 Study Questions Value of Calcium and Vitamin D Supplements for Certain Men with Prostate Cancer | Prescribing calcium and vitamin D supplements for men at risk of bone loss from hormonal treatment for prostate cancer seems like good medicine.
- 8/6/2012 Edinburgh Study Pinpoints Prostate Cancer 'Growth' Gene | Scientists from Edinburgh University have pinpointed a gene they say could lead to improvements in the diagnosis and treatment of prostate cancer.
- 7/25/2012 Phase III Clinical Trial Opens In Republic of South Africa, Enrolls First Patient | The first prostate cancer patient enrolled in a Phase III clinical trial and began receiving treatment on the investigational therapeutic agent Debio 8206.
- 7/25/2012 Protein Brings New Light to Understanding Prostate Cancer | The holy grail of prostate cancer is to figure out why cells stop responding to hormone therapy.
- 7/18/2012 Landmark Study Comparing Surgical Intervention to Watchful Waiting in Men With Low Risk Prostate Cancer Shows Certain Men May Safely Forgo Surgery | The study shows that a subset of men who are properly selected can safely choose either active surveillance or a watchful waiting management approach of their diagnosed prostate cancers
- 7/16/2012 New Cancer Biomodule Regulating Prostate Cancer Initiation and Progression Identified | Proteins in the Hox regulatory network identified as potential tumor suppressors in prostate cancer initiation and progression.
- 7/6/2012 TMPRSS2-ERG and Prostate Cancer Outcomes after Prostatectomy | New study shows common prostate cancer mutation does not strongly predict disease recurrence or mortality among men treated with radical prostatectomy
- 6/20/2012 Major Advancements Being Made Against Prostate Cancer, says FDA Cancer Drug Chief | For many cancer patients, treatment options remained in a holding pattern for far too long.
- 6/20/2012 A Protein Unique to Prostate Cancer Has Been Identified | Protein may be used as a biomarker to distinguish indolent from lethal disease and serve as a novel drug target
- 6/20/2012 Prostate Cancer Cell Line Study Shows Potential New Route to Cancer Progression--SLC45A3-ELK4 Fusion | A study published in Cancer Discovery has identified an unusual pathway to prostate cancer progression.
- 6/5/2012 Denosumab Prolonging Bone-Metastasis Free Survival Featured at ASCO | The research team found that patients with shortened PSADT are at higher risk of developing bone metastasis, and denosumab is markedly effective at prolonging BMFS in the study’s selected subset of patients.
- 6/5/2012 Radium-223 dichloride Proves Promising in Metastatic Prostate Cancer | The ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer) trial used Radium-223 in treatment-resistant, metastatic prostate cancer patients and bone metastases.
- 6/5/2012 Investigational Drug OGX-247 Shows Patient Benefit in Phase II Clinical Trials | "We are encouraged by these early data that further support the ability of OGX-427 to suppress androgen receptor activity and tumor cell survival"
- 6/5/2012 RNA Prognostic Model Predicts Survival for Men with Prostate Cancer | Results found that the six-gene model suggests possible dysregulation in the system, which researchers believe requires further study.
- 6/4/2012 Moving Research and Management Forward For Men with Treatment-Resistant Metastatic Prostate Cancer | So, what’s next? Presenters posed the question of what optimal sequences or therapies exist for men with treatment-resistant, metastatic prostate cancer?
- 6/4/2012 Phase I Clinical Trial Reveals Positive Immune Response in Cancers, Including Prostate | The Phase I clinical trial was conducted at five centers throughout the United States.
- 6/4/2012 Phase III Trial Results for Circulating Tumor Cell Counts and Overall Survival | Though researchers understand that CTC’s are promising biomarkers in treatment-resistant, metastatic prostate cancer, it has not been validated for docetaxel treatment.
- 6/4/2012 Cancer Antigen MICA Plays Vital Role in Immune Surveillance | Immunotherapy research remains as a promising modality for the treatment of cancer, including prostate cancer—as well as an important tool in clarifying the mechanism of action for guiding patient selection.
- 6/4/2012 Phase III Study of Abiraterone Acetate in Metastatic Disease Presented at ASCO | Results from a Phase III clinical trial were presented at the annual American Society of Clinical Oncology (ASCO) meeting today.
- 6/3/2012 Practice Changing Data Results from 17 Year Study Presented at ASCO | Investigational researcher Maha Hussain, MD, FACP of the University of Michigan Comprehensive Cancer Center presented pivotal research at the 12th annual American Society of Clinical Oncology (ASCO) meeting.
- 6/3/2012 PROSTVAC Vaccine for Prostate Cancer to Enter Phase III Clinical Trials | PROSTVAC, a virus-based vaccine, successful showed an average 8.5 month overall survival benefit and favorable side effects in Phase II clinical trials
- 6/3/2012 Liver Metastases Help Predict Overall Survival in Metastatic Prostate Cancer Patients | A collaborative research team studied liver metastases in relation to overall survival in men with treatment-resistant metastatic prostate cancer (TRMPCa).
- 6/3/2012 PSA Decline Found in Phase I Clinical Trial Using KX2-391, Funding from PCCTC | The drug is potent against a broad range of solid tumor cell types, as well as many leukemia types, including those resistant to imatinib and/or dasatinib.
- 6/3/2012 Phase III Clinical Trial Compares Efficacy of Ipilimumab in Metastatic Prostate Cancer Patients | Ipilimumab is a fully human monoclonal antibody that augments antitumor response and is also responsible for blocking CTLA-4 (a protein that plays an important regulatory role in the immune system).
- 6/2/2012 Team of PCF-Funded Researchers Present MDV3100 Trial Results at ASCO | The clinical advancement of MDV3100 is one of the most important events in the history of prostate cancer research and the Prostate Cancer Foundation
- 6/2/2012 Testosterone Levels Studied in Neoadjuvant Trial | A team of prostate cancer researchers presented data during the annual ASCO conference on neoadjuvant (administration of therapeutic agents before a main treatment) androgen pathway suppression prior to prostatectomy.
- 5/31/2013 Funding from PCCTC Advances Study of Ketoconazole and Docetaxel Response Following Abiraterone Acetate | Ketoconazole (keto) is drug used in prostate cancer to block the release of testosterone from the adrenal glands, typically administered in conjunction with steroids to avoid side effects.
- 5/21/2012 Molecular Subtype of Prostate Cancer Discovered with Funding from PCF | Defect in SPOP gene found in up to 15 percent of all prostate tumors, aggressiveness yet to be determined
- 5/15/2012 DNA Biomarker Discovery Focuses on DNA Methylation | Published in Clinical Cancer Research today, Krishna Donkena, PhD and her research team at the Mayo Clinic found that DNA biomarkers produced by DNA methylation may be used to better detect prostate cancer recurrence and metastases.
- 4/23/2012 PCF-Funded Young Investigator, Dr. Tarek Bismar, Awarded Donald Coffey Prize for the Best Research Paper by BJUI | PCF-funded Young Investigator, Dr. Tarek Bismar, was awarded the Donald Coffey Prize for the best research paper of 2011, titled "PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer."
- 4/17/2012 Proton Therapy Update: No Evidence That Benefits Justify Cost | Dr. Matthew Cooperberg suggested that IMRT was associated with better results in the article, though it did cause more erectile dysfunction than 3D conformal radiation.
- 4/17/2012 HIFU Technology Progresses, More Clinical Research Is Needed | A recent study conducted at the University College London shows that HIFU may offer the promise of effective ablation in low-grade lesions, if all cancer cells can be reached.
- 4/9/2012 Prostate and Breast Cancer Vaccine Progressing | The progress of vaccines continue to progress and PCF is pleased to see a growing interest in the field.
- 4/5/2012 PCF Researcher Dr. Carl June Presents Results on "Performance Enhanced" T-Cell Therapy in Leukemia | Dr. June described a therapeutic method that successfully used a patient’s own lymphocytes to treat a type of leukemia.
- 4/5/2012 Dr. Karen Knudsen Identifies "Next Generation" Gene Targets for Prostate Cancer | Karen Knudsen, PhD participated in a session at the AACR conference focused on identifying the next generation of gene targets for prostate cancer.
- 4/5/2012 PCF Scientific Advisory Board Member Martin G. Pomper Speaks on Molecular Imagining and Theranostics | Dr. Martin G. Pomper, reported on the increased need for studies of the genetic and molecular basis of cancer, including the use of molecular imaging for the use of noninvasive analysis of cancer biology in vivo.
- 4/4/2012Dr. Charles Sawyers Discusses the Coming of Age in Pathway-Targeted Therapeutics, MDV3100 | During a plenary session at the AACR conference, panel speakers discussed therapies targeting oncogenic signaling pathways and their continued maturity within the field of cancer research.
- 4/4/2012 Data Presented by Dr. Sarah Nechuta on the Role of Cruciferous Vegetables and Sulphorophane in Broccoli | Over the past 19 years, PCF funding has stimulated some of the most rigorous nutrition and diet research of any cancer research funding agency.
- 4/4/2012 Correlation Between Excess Body Weight and Prostate Cancer Identified by Dr. Vincent Freeman | Endpoint results showed that the risk for cancer recurrence increased with increasing BMI
- 4/4/2012 First Prostate Nanomedicine Shows Positive Results in Phase I Trials | This research represents the first time a nanomedicine has moved from the test tube to the clinic to target prostate cancer cells effectively and to deliver docetaxel in high concentrations safely.
- 4/4/2012 PCF-Supported Researcher Dr. Chuck Ryan Focuses on New Prostate Cancer Drugs | Dr. Charles Ryan presented data results on agents used in the treatment of prostate and genitourinary cancers at the 103rd annual AACR conference.
- 4/3/2012 PCF-Funded Investigator Presents on Investigational Drug Galeterone | Galeterone showed great than 30% PSA reduction in all patients with some patients demonstrating 90% PSA declines.
- 4/3/2012 Dr. Gulley, PCF-Supported Scientist, Discusses Differences in Targeted and Immune Therapies | PCF-supported researcher Dr. James Gulley presented data results during the plenary session at the AACR conference today.
- 4/3/2012 PCF-Funded Young Investigator Presents Research on Imaging Androgen Receptor Signaling | Dr. Ulmert and his research teams’ work are focused on the development of radiotracers to detect cancers or monitor treatment responses, with specific attention to clearer usage in the clinic.
- 4/3/2012 Bringing Next-Generation Sequencing to the Cancer Clinic for Precision Medicine | Recent advances in next generation sequencing afford new opportunities to uncover specific genetic mutations that drive cancers.
- 4/2/2012 PCF-Funded Researcher Presents Data on Chromatin States Found In Stem Cells | Dr. De Marzo at Johns Hopkins Department of Pathology and graduate student colleague Laxmi Pellakuru presented a poster session focused on understanding how molecular mechanisms are responsible for altering chromatin states in stem cells and cancer cells.
- 4/2/2012 PCF Partner Institutions Honored at AACR Opening Ceremony | The opening ceremony at the American Association of Cancer Research (AACR) conference awarded two PCF-supported institutions, the Institute of Cancer Research (ICR) and the Royal Marsden Hospital, with the AACR Team Science Award.
- 4/2/2012 PCF Award Recipient Steven Balk Chairs Session on Advances in Androgen Receptor Discovery | Prostate Cancer Foundation Challenge Award recipient, Steven P. Balk at Beth Israel Deaconess Medical Center in Boston, MA chaired a session focused on recent advances made in targeting androgen receptors for prostate cancer prevention and therapy.
- 4/1/2012 PCF-Funded Scientists Say Diabetes Medication Shows Promise Against Cancers, Including Prostate | Data presented at the annual AACR meeting on metformin showed promising results against a variety of different cancers, including prostate cancer
- 4/1/2012 Robotic High-Throughput Screen Featured at AACR | William Sellers, Vice President of Oncology at Novartis Institutes of Biomedical Research, featured the development of a robotic high-throughput screen that allows testing 1,300 drugs on 70 different cancer cell lines, while at the same time, generates 27 million data points.
- 4/1/2012 PCF Support Facilitates AACR Recognition Awards | During the American Association for Cancer Research (AACR) annual meeting, titled "Accelerating Science: Concept to Clinic," three Prostate Cancer Foundation supported researchers were recognized for their early-career efforts in the field of prostate cancer research.
- 3/23/2012 Dr. Ballentine Carter Elected Trustee of the American Board of Urology | Dr. Ballentine Carter, a Prostate Cancer Foundation (PCF) funded researcher, mentor and sterling clinician, was elected Trustee of the American Board of Urology (ABU), beginning his six-year term on February 28, 2012.
- 3/23/2012 Dr. Charles Sawyers Elected AACR President | "Dr. Sawyers is an outstanding leader and mentor of young scientists in the field of cancer research"
- 3/22/2012 Scientists Identify New Mechanism of Prostate Cancer Cell Metabolism | Dr. Charles Sawyers, Prostate Cancer Foundation funded researcher since 1996, supporter and long-time friend, was named president-elect of the American Association for Cancer Research (AACR) and will begin his term in April 2013.
- 3/14/2012 Dr. Patrick Walsh, Renowned Prostate Cancer Researcher, Receives the Amory Prize | Patrick Walsh, MD, of Johns Hopkins University School of Medicine, today received the prestigious Amory Prize award from the American Academy of Arts and Sciences.
- 3/12/2012 PCF Initiates China Research Program | The Prostate Cancer Foundation (PCF) launched a new research initiative in China, partnering with the Chinese Urological Association, in an effort to promote and fund prostate cancer research.
- 3/9/2012 Novel Therapy Zytiga Approved by FDA for Metastatic Prostate Cancer | Zytiga® (abiraterone acetate) was approved by the US Food and Drug Administration in April 2011 for the treatment of metastatic castration-resistant prostate cancer (mCRPC), following docetaxel chemotherapy.
- 3/9/2012 PCF Announces Winners of Young Investigator Award in China | The Prostate Cancer Foundation announced its first two Young Investigators in China to launch its initiative to identify, fund and promote innovative research projects within China.
- 3/8/2012 China on Front Lines of Fight Against Prostate Cancer | How does the body of a Chinese farmer differ from that of his African-American counterpart?
- 2/27/2012 A Driver of Prostate Cancer Progression Identified by Two PCF-Funded Researchers | The article below was funded by two PCF Competitive Awards (valued at $100,000 each)
- 2/27/2012 Cancer Discovery Shows Promise of New Drugs | Researchers at the University of California, San Francisco discovered how a protein can go awry, leading to prostate cancer metastasis.
- 2/24/2012 Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data | Active Biotech's (NASDAQ OMX NORDIC: ACTI) and Ipsen's castrate resistant prostate cancer project, TASQ will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.
- 2/13/2012 Nerve Sparing Study Plays Important Role in Sexual Function | The vast majority of men who have a prostate cancer operation can retain their ability to orgasm if the surgery is carried out without removing the nerves that surround the prostate gland like a hammock, according to a study in the February issue of the urology journal BJUI.
- 2/10/2012 Mentorship and Data Exchange Expand Prostate Cancer Research | Researchers at Thomas Jefferson University are investigating the role of curcumin (a spice originating in India) and its role in slowing prostate cancer tumor growth.
- 2/9/2012 Heart Disease May Be a Risk Factor for Prostate Cancer | In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
- 2/9/2012 Brachytherapy Can Be Successful for High-Risk Prostate Cases, Too | Although brachytherapy has not been considered a highly effective form of treatment for high-risk prostate cancer, it was shown to reduce prostate cancer–specific mortality (PCSM) compared with external beam radiation therapy (EBRT) alone in a recent large analysis.
- 2/8/2012 ProstaCaid™ Inhibits Tumor Growth in a Xenograft Model of Human Prostate Cancer [JOURNAL] | We have recently demonstrated that the dietary supplement ProstaCaid™ (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro.
- 2/8/2012 Third Peer-Reviewed Study Proves Botanical Formula Fights Prostate Cancer Without Toxicity | Scientists at Indiana University, Methodist Research Institute, study a botanical formula that kills aggressive prostate cancer tumors
- 2/7/2012 Urine Test Could Supplement Prostate Cancer Biopsy | PCF funding continues to advance early diagnostics
- 2/7/2012 Fast Track Treatment Continues to Make Progress | On June 6, 2011, the Prostate Cancer Foundation reported promising Phase III clinical trial results for Radium-223 (Alpharadin) that were presented at the annual American Society of Clinical Oncology meeting in Chicago.
- 2/2/2011 OGX-427 Used with Prednisone Shows Promising Results for Prostate Cancer Patients | A panel of PCF-Safeway funded Canadian and U.S. researchers presented data from a Phase II clinical trial using OGX-427 in combination with prednisone versus prednisone alone at the 2012 ASCO Genitourinary meeting this week in San Francisco.
- 2/2/2012 Promising New Therapeutic Targets Bone and Disperses Radiation | Alpharadin may decreases bone metastases and reduce death
- 2/1/2012 Researchers’ Work in Prostate Cancer and Exercise Advances | June Chan focuses on early-stage disease
- 1/27/2012 PCF Lays the Foundation for Roswell Park Vaccine Trial | Prostate Cancer Foundation funding to Drs. Jim Allison and Padmanee Sharma (who studied NY-ESO-1 and other tumor antigens for chemotherapy) provided a foundation for a research breakthrough made at Roswell Park Cancer Center.
- 1/11/2012 A Model For Life Sciences Research Funding | Ever wonder where the money goes when you donate to a large “Fight This Cancer” campaign?
- 1/5/2012 Energy and Advocacy Preserve Crucial PCa Research Funds | With efforts from the Prostate Cancer Foundation and the U.S. prostate cancer advocacy community, led by the Prostate Cancer Roundtable, the 2012 budget for Congressionally Directed Medical Research Programs was preserved.
- 11/3/2011 PCF Funding Leads to MDV3100 Clinical Successes | All trial participants receive drug, not placebo.
- 11/1/2011 Dr. Oliver Sartor on Radium-223 at 2011 PCF Scientific Retreat | Dr. Oliver Sartor, a member of the PCF Research Community, was the principal investigator for the study sites in the United States.
- 11/1/2011 AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy | PCF-funded researchers partner with AgonOx Partners and MedImmune to develop tumor-specific agonist.
- 9/27/2011 U.S. Scientists Map Genome of Advanced Prostate Cancer | Researchers discover genetic 'hypermutations' that help tumors resist common therapies
- 9/19/2011 FDA Expands Approval for Denosumab | On Friday, September 16, 2011, the Food and Drug Administration (FDA) approved denosumab (Prolia) to increase bone mass in non-metastatic prostate cancer patients undergoing androgen deprivation therapy (ADT).
- 9/7/2011 Abiraterone (Zytiga) Approved in European Union | Today’s approval of Abiraterone (Zytiga) in the European Union (EU) offers a new treatment option for more than 70,000 patients living with prostate cancer in European member states.
- 8/23/2011 FDA to Decide by April 26 on New Xgeva Application| Prevention of metastases represents promising new use for Xgeva
- 8/23/2011 FDA Grants Fast Track Designation to Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone| Decision may make new treatment available for patients faster
- 8/22/2011 5-Gene Signature Identifies Lethal Varieties of Prostate Cancer and May Better Direct Patients to Appropriate Levels of Treatment | Discovery enabled by collaborative effort of scientists at more than a dozen institutes in U.S. and Sweden
- 7/29/2011 UT Southwestern PCF Young Investigator Identifies New Pathway Explaining Resistance to Prostate Cancer Treatment | Discovery Opens Door to New Target for Drug Development
- 7/28/2011 Abiraterone (Zytiga) Approved in Canada | Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), the oral medication for the treatment of men with metastatic prostate cancer.
- 7/27/2011 Intermittent Androgen Deprivation | Changing the standard of care for men with recurrent prostate cancer
- 7/25/2011 Final European Approval of Abiraterone (Zytiga) Expected Within Weeks | Approval will open new treatment option for more than 70,000 patients each year in the EU
- 7/6/2011 Stearns' Amendment to Increase Prostate Cancer Research under Department of Defense Gets Bipartisan Approval | $16 Million Increase in Prostate Cancer Research Adopted by Voice Vote
- 6/27/2011 Duke Team Finds New Clues to How Cancer Spreads | PCF-funded investigator lead author of the study
- 6/6/2011 News from ASCO: Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients | Good news for patients with castration-resistant prostate cancer that has spread to the bone
- 5/30/2011 Medicare Moves to Pay for Prostate Cancer Drug Provenge | This is encouraging news for many prostate cancer patients with advanced metastatic disease who may benefit from treatment with Provenge.
- 5/23/2011 Half of Prostate Cancers Could Potentially Benefit From New Type of Cancer Drugs | Work was a team effort led by PCF-funded investigator Dr. Arul Chinnaiyan
- 4/19/2011 KRAS Gene Fusion in Prostate Cancer | This recently published study suggests that rare gene fusions or rearrangements of a gene called KRAS, may be associated with more aggressive metastatic prostate cancers and tumor progression.
- 3/25/2011 FDA Approves Drug Found to Prolong Lives of Melanoma Patients | Today’s FDA approval of ipilimumab for the treatment of malignant melanoma is the second immunotherapy approved for the treatment of cancer.
- 3/24/2011 Prostate Cancer Spreads to Bones by Overtaking the Home of Blood Stem Cells | Like bad neighbors who decide to go wreck another community, prostate and breast cancer usually recur in the bone, according to a new University of Michigan study.
- 3/7/2011 UCLA Researchers Use 'Nano-Velcro' Technology to Improve Capture of Circulating Cancer Cells | New method may help improve diagnosis and treatment-monitoring of cancer
- 3/2/2011 Scientists Target Aggressive Prostate Cancer | SPINK1 gene could be to prostate cancer what HER2 has become for breast cancer
- 2/9/2011 First Look at Prostate Cancer Genome Yields Insights | Newly detected DNA changes may eventually lead to better treatments
- 1/4/2011 PCF $3 Million Investment in Circulating Tumor Cells Delivers Ten‐Fold Investment by Johnson & Johnson within Three Years | Circulating tumor cells (CTCs), found in patients’ bloodstreams, are shed from tumors and may be responsible for metastases.
- 12/3/2010 Scientists Find Protein That May Help Control Prostate Cancer | Discovery could aid in limiting tumor growth and progression, expert says
- 10/11/2010 Abiraterone Offers Hope in Advanced Prostate Cancer | Drug may reach market next year
- 7/20/2010 FDA Grants Denosumab Priority Review for Cancer-Related Bone Loss | The FDA has granted denosumab priority review for treatment of bone loss and fractures in patients with advanced prostate cancer.
- 6/17/2010 Cabazitaxel (Jevtana) Approved for Advanced Prostate Cancer | When disease continues to worsen after treatment with standard drug
- 4/29/2010 Prostate Cancer Vaccine Gains FDA Approval | The History of Provenge